PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan

Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.

Inclusion Criteria:

• GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan
• Patients who have never been treated with Spesolimab I.V. Infusion before enrolment

Exclusion Criteria:

• None